Motility modulation beyond MCP and domperidon: Mechanisms of action of a clinically proven medicine, STW 5, in functional GI diseases

Introduction: Motility-modulating drugs have been an important therapeutic approach in functional GI diseases. This approach has been questioned by the withdrawal of the prokinetic drug cisapride from the market and now again by the referrals for metoclopramide (MCP) and domperidon leading to the omission of functional dyspepsia and gastrooesophageal reflux disease from its therapeutic indications. As has been recently shown by a clinical review publication (1), an herbal medicinal product, STW 5, is a safe and therapeutically effective treatment option in these indications. Material and Methods: For identifying…